Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis

British Journal of Rheumatology

Volumn 35, Issue 5, 1996, Pages 416-423

  Ronday, H K ^a,b   Smits, H H ^b   Van Muijen, G N P ^c   Pruszczynski, M S M ^c   Dolhain, R J E M ^a   Van Langelaan, E J ^d   Breedveld, F C ^a   Verheijen, J H ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RIJNLAND HOSPITAL   (Netherlands)

Author keywords

Immunohistochemistry; Osteoarthritis; Plasminogen activation; Rheumatoid arthritis; Urokinase

Indexed keywords

FIBRIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE;

ARTICLE; CLINICAL ARTICLE; GENE EXPRESSION; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIUM;

EID: 0029934524     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/35.5.416     Document Type: Article

References (37)

1. Werb Z, Alexander CM. Proteinases and matrix degradation. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology, 4th edn. Philadelphia: W B Saunders Company, 1993:248-69.
2. Yates DB, Scott JT. Rheumatoid synovitis and joint disease. Ann Rheum Dis 1975;34:1-6.
3. Zvaifler NJ, Firestein GS. Pannus and pannocytes, alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum 1994;37:783-9.
4. Hamilton JA. Plasminogen activator activity of rheumatoid and nonrheumatoid synovial fibroblasts. J Rheumatol 1982;9:834-42.
5. Inman RD, Harpel PC. α2-Plasmin inhibitor-plasmin complexes in synovial fluid. J Rheumatol 1986;13:535-7.
6. Kikuchi H, Tanaka S, Matsuo O. Plasminogen activator in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 1987;14:439-45.
7. Vassali J-D, Sappino A-P, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991;88:1067-72.
8. Quax PHA, Van Muijen GNP, Pedersen N et al. The plasminogen activator system in extracellular matrix degradation. Fibrinolysis 1992;6(suppl. 4):41-4.
9. Werb Z, Mainardi MD, Vater CA, Harris ED. Endogenous activation of latent collagenase by rheumatoid synovial cells. N Engl J Med 1977;296: 1017-23.
10. Murphy G, Atkinson S, Ward A, Gavrilovic J, Reynolds JJ. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. In: Brakman P, Kluft C, eds. Plasminogen activation in fibrinolysis, in tissue remodeling and in development. Ann N Y Acad Sci 1992;667:1-12.
11. Vassali J-D, Baccino D, Belin D. A cellular binding site for the Mr 55.000 form of human plasminogen activator, urokinase. J Cell Biol 1985;100:86-92.
12. Mochan E, Uhl J. Elevations in synovial fluid plasminogen activator in patients with rheumatoid arthritis. J Rheumatol 1984;11:123-8.
13. Kummer JA, Abbink JJ, De Boer JP et al. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases. Arthritis Rheum 1992;35:884-93.
14. Saxne T, Lecander I, Geborek P. Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. J Rheumatol 1993;20:91-6.
15. Brommer EJP, Dooijewaard G, Dijkmans BAC, Breedveld FC. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation. Thromb Haemostasis 1992;68:180-4.
16. Campbell IK, Picolli DS, Roberts MJ, Muirden KD, Hamilton JA. Effects of tumor necrosis factor α and β on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis Rheum 1990;33:542-52.
17. Medcalf RL, Hamilton JA. Human synovial fibroblasts produce urokinase-type plasminogen activator. Arthritis Rheum 1986;29:1397-401.
18. Kirchheimer JC, Remold HG, Wanivenhaus A, Binder BR. Increased proteolytic activity on the surface of monocytes from patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1430-3.
19. Hamilton JA, Hart PH, Leizer T, Vitti GF, Campbell IK. Regulation of plasminogen activator activity in arthritic joints. J Rheumatol 1991;18(suppl. 27):106-9.
20. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Kellgren JH, Lawrence JS. Radiologic assessment of osteoarthritis. Ann Rheum Dis 1957;16:494-502.
22. De Bruin PAF, Verspaget HW, Griffioen G, Nap M, Verheijen JH, Lamers CBHW. Plasminogen activator activity and composition in human colorectal carcinomas. Fibrinolysis 1989;1:57-62.
23. Lowry OH, Rosebrough NJ, Fair AL, Randall R. Protein measurement with folin phenol reagent. J Biol Chem 1951;193:265-275.
24. Koolwijk P, Miltenburg AMM, Van Erck MGM et al. Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator (u-PA) in synovial fluids of arthritis patients. Correlation with clinical and experimental parameters. J Rheumatol 1995;22:385-93.
25. Dooijewaard G, van Iersel JJL, Brommer EJP. Quantitation of pro-UK, UK and UK-inhibitor levels in plasma of patients and healthy men. Fibrinolysis 1986; suppl. 1:142.
26. De Vries TJ, Quax PHA, Denijn M et al. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994;144:70-82.
27. De Bruin PAF, Crama-Bohbouth G, Verspaghet HW et al. Plasminogen activators in the intestine of patients with inflammatory bowel disease. Thromb Haemostasis 1988;60:262-6.
28. Graeff H, Harbeck N, Fache L, Wilhelm O, Jänicke F, Schmitt M. Prognostic impact and clinical relevance of tumor-associated proteases in breast cancer. Fibrinolysis 1992;6(suppl. 4):45-53.
29. Ganesh S, Sier CFM, Griffioen G et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer tissue. Cancer Res 1994;54: 4065-71.
30. Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell-surface bound urokinase. J Cell Biol 1988;107:2437-45.
31. Pöllänen J, Saksela O, Salonen EM et al. Distinct localization of urokinase-type plasminogen activator and its type-1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 1987;104:1085-96.
32. Schwartz BS. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activer inhibitor type 2. J Biol Chem 1994;269:8319-23.
33. Machanda N, Schwartz BS. Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytes. J Biol Chem 1991;266:14580-4.
34. Blasi F. Urokinase and urokinase receptor: a paracrine/ autocrine system regulating cell migration and invasiveness. Bioessays 1993;15:105-10.
35. Quax PHA, Pedersen N, Masucci MT et al. Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regul 1991;2:793-803.
36. Kobayashi H, Gotoh J, Fujie M, Shinohara H, Moniwa N. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer 1994;57:727-33.
37. De Vries TJ, Mooy CM, Van Balken MR et al. Components of the plasminogen activation system in uveal melanoma. A clinico-pathological study. J Pathol 1995;175:59-67.